Open Access

Use of incretin-based therapies.

Congress Session

About the speaker

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
32 presentations
0 follower

3 more presentations in this session

Epigenetic signatures and cardiovascular risk in diabetes.

Speaker: Professor F. Cosentino (Stockholm, SE)


Mechanisms of cardiovascular impact of SGLT2 inhibitors.

Speaker: Professor B. Staels (Lille Cedex, FR)


SGLT2 inhibitors and alteration of substrate metabolism.

Speaker: Professor E. Ferrannini (Pisa, IT)


Access the full session

How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

Speakers: Professor L. Ryden, Professor F. Cosentino, Professor B. Staels, Professor E. Ferrannini

About the event


ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk